The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

As a leader in its category, Sinotau is probably hoping to follow in the footsteps of Hengrui Pharmaceuticals (1276.HK; ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Cardinal Health's growth faces challenges from tariff risks, regulatory uncertainties, and competitive pressures. Learn more ...

BC Cancer – Victoria will soon begin offering ​prostate-specific membrane antigen (PSMA) positron emission tomography (PET) ...